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Since the discovery of the first receptor tyrosine kinase (RTK) more 
than a quarter of a century ago, many members of this family of 
cell-surface receptors have emerged as key regulators of critical 
cellular processes, such as proliferation and differentiation, cell 
survival and metabolism, cell migration, and cell-cycle control 
(Blume-Jensen and Hunter, 2001; Ullrich and Schlessinger, 1990). 
Humans have 58 known RTKs, which fall into 20 subfamilies (Fig-
ure 1). All RTKs have a similar molecular architecture, with ligand-
binding domains in the extracellular region, a single transmem-
brane helix, and a cytoplasmic region that contains the protein 
tyrosine kinase (TK) domain plus additional carboxy (C-) terminal 
and juxtamembrane regulatory regions. The overall topology of 
RTKs, their mechanism of activation, and key components of the 
intracellular signaling pathways that they trigger are highly con-
served in evolution from the nematode Caenorhabditis elegans 
to humans, which is consistent with the key regulatory roles that 
they play. Furthermore, numerous diseases result from genetic 
changes or abnormalities that alter the activity, abundance, cel-
lular distribution, or regulation of RTKs. Mutations in RTKs and 
aberrant activation of their intracellular signaling pathways have 
been causally linked to cancers, diabetes, inflammation, severe 
bone disorders, arteriosclerosis and angiogenesis. These con-
nections have driven the development of a new generation of 
drugs that block or attenuate RTK activity.
In this Review, we discuss insights into the mechanism of RTK 
regulation that have emerged from recent structural and func-
tional studies. We examine prevailing concepts that underlie the 
activation of intracellular signaling pathways following growth 
factor binding to RTKs. We also consider recent systems biology 
approaches for understanding the complicated circuits and net-
works that result from the interplay among the multiple signaling 
pathways activated by RTKs. Finally, we describe the impact of 
these advances on the discovery and application of new thera-
pies for cancers and other diseases driven by activated RTKs.
Mechanisms of Receptor Activation
In general, growth factor binding activates RTKs by inducing 
receptor dimerization (Ullrich and Schlessinger, 1990). How-
ever, before discussing this aspect of RTK regulation, it is 
important to note that a subset of RTKs forms oligomers even 
in the absence of activating ligand. For example, the insulin 
receptor and IGF1 receptor are expressed on the cell surface 
as disulfide-linked (αβ)2 dimers (Ward et al., 2007). Binding of 
insulin or IGF1 induces structural changes within these dimeric 
receptors that stimulate tyrosine kinase activity and cell sig-
naling. Some studies have suggested that epidermal growth 
factor (EGF) binds to and activates pre-existing oligomers of 
its receptor (Clayton et al., 2005; Gadella and Jovin, 1995), but 
the precise nature and size of these oligomers are not known. 
Moreover, there is evidence that activation of certain RTKs, 
such as Tie2 (an angiopoietin receptor) and Eph receptors, 
may require the formation of larger oligomers (Barton et al., 
2006; Himanen and Nikolov, 2003).
Whether the “inactive” state is monomeric or oligomeric, 
activation of the receptor still requires the bound ligand to 
stabilize a specific relationship between individual receptor 
molecules in an “active” dimer or oligomer. Structural studies 
of the extracellular regions of RTKs have provided clear views 
of how ligand binding can drive dimerization. In addition, the 
single membrane-spanning α helix may contribute to dimeriza-
tion in some cases, although its precise role is not yet clear. 
In the ligand-bound receptor, self-association of the extracel-
lular region is thought to guide the intracellular domains into 
a dimeric conformation that activates their tyrosine kinase 
domains through the mechanisms discussed below. One 
receptor in the dimer/oligomer then phosphorylates one or 
more tyrosines in a neighboring RTK, and the phosphorylated 
receptor then serves as a site for assembly (and activation) 
of intracellular signaling proteins (Ullrich and Schlessinger, 
1990).
Ligand-Induced Dimerization of RTK Extracellular 
Regions
Early studies of RTKs and cytokine receptors suggested a 
conceptually straightforward mechanism for ligand-induced 
dimerization: a bivalent ligand interacts simultaneously with 
two receptor molecules and effectively crosslinks them into 
a dimeric complex. This “ligand-mediated” mode of receptor 
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dimerization was further supported by crystal structures of 
several fragments of the ligand-binding domains from RTKs 
bound to their relevant ligands. Examples include the stem cell 
factor receptor KIT (Liu et al., 2007), the Flt1 vascular endothe-
lial growth factor (VEGF) receptor (Leppänen et al., 2010; Wies-
mann et al., 1997), the nerve growth factor (NGF)/neurotrophin 
receptor TrkA (Wiesmann et al., 1999), Axl (Sasaki et al., 2006), 
Tie2 (Barton et al., 2006), and Eph receptors (Himanen and 
Nikolov, 2003). In each of these cases, the ligand is itself a 
dimer and simply crosslinks the ligand-binding fragments of 
two receptor molecules. Recent structures of more complete 
extracellular regions of RTKs have provided important addi-
tional insight into the range of mechanisms used for ligand-
induced dimerization. Figure 2 illustrates two mechanistic 
extremes and two intermediate cases. At one extreme, receptor 
dimerization is entirely “ligand mediated” and the two recep-
tors make no direct contact (Figure 2A). At the other extreme, 
dimerization is instead entirely “receptor mediated” (Figure 
Figure 1. Receptor Tyrosine Kinase Families
Human receptor tyrosine kinases (RTKs) contain 20 subfamilies, shown here schematically with the family members listed beneath each receptor. Structural 
domains in the extracellular regions, identified by structure determination or sequence analysis, are marked according to the key. The intracellular domains are 
shown as red rectangles.
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2D), and the ligand makes no direct contribution to the dimer 
interface. Alternatively, dimerization can involve a combination 
of ligand-mediated and receptor-mediated components (Fig-
ures 2B and 2C). Dimerization of most RTKs is likely to resem-
ble one of these four modes. However, additional paradigms 
are likely to emerge from more comprehensive studies of other 
RTK families.
TrkA: Ligand-Mediated Dimerization (Figure 2A)
The TrkA (NGF receptor) extracellular region contains a sole-
noid-like leucine-rich repeat (LRR) region followed by two 
immunoglobulin-like domains (Ig-C1 and Ig-C2). In the NGF-
induced dimer, the extracellular regions of the two TrkA mol-
ecules do not contact one another. Only the Ig-C2 domain of 
each receptor molecule contacts the dimeric NGF ligand, with 
each Ig-C2 contacting both chains of the NGF dimer (Weh-
rman et al., 2007; Wiesmann et al., 1999). Thus, the bound NGF 
Figure 2. Receptor Tyrosine Kinase Dimerization and Kinase 
 Activation
Top: In general, receptor tyrosine kinases (RTKs) associate into dimers when 
ligand (red) binds to their extracellular regions. The bound ligand can form 
all, a portion, or none of the dimer interface, and it activates the receptors by 
stabilizing a specific relationship between two individual receptor molecules.
(A) A nerve growth factor dimer (red) crosslinks two TrkA molecules without 
any direct contact between the two receptors (Wehrman et al., 2007). 
(B) A stem cell factor dimer (red) also crosslinks two KIT molecules. In addi-
tion, two Ig-like domains (D4 and D5), which reorient upon receptor activation, 
interact across the dimer interface (Yuzawa et al., 2007). Thus, KIT combines 
ligand-mediated and receptor-mediated dimerization modes. 
(C) Two fibroblast growth factor receptor (FGFR) molecules contact one 
another through the Ig-like domain D2, and the accessory molecule hepa-
rin or heparin sulfate proteoglycans (white sticks) also contact this domain 
(Schlessinger et al., 2000). In addition, each fibroblast growth factor molecule 
(red) contacts Ig-like domains D2 and D3 of both FGFR molecules. 
(D) Dimerization of ErbB receptors is mediated entirely by the receptor. Bind-
ing simultaneously to two sites (DI and DIII) within the same receptor molecule, 
the ligand drives conformational changes in epidermal growth factor receptor 
(EGFR) that expose a previously occluded dimerization site in domain II.
Bottom: Dimerization of the extracellular regions of RTKs activates the intra-
cellular tyrosine kinase domains (TKDs), which contain a C-lobe (light purple), 
N-lobe (dark purple or yellow in the inactive and active states, respectively), 
and an activation loop (purple or yellow in the inactive and active states, re-
spectively). Although the crystal structures of the activated TKDs are very 
similar (Huse and Kuriyan, 2002), structures of inactive TKDs differ substan-
tially among the receptors (top row), reflecting the diversity in their regulatory 
mechanisms. However, many receptors are inhibited by a set of intramolecu-
lar (or cis) interactions:
(E) Insulin receptor-like (activation loop inhibition). In FGFR, insulin receptor, 
and IGF1 receptor, the activation loop interacts directly with the active site of 
the kinase and blocks access to protein substrates (in FGFR) or to both ATP 
and protein substrates (in insulin and IGF1 receptors). Phosphorylation of key 
tyrosines (“Y”) disrupts these autoinhibitory interactions and allows the kinase 
to “relax” to the active state.
KIT-like (juxtamembrane inhibition). In KIT, PDFGR, and Eph receptors, the 
juxtamembrane region (red) interacts with elements within the active site of 
the kinase (including the αC helix and the activation loop) to stabilize an in-
active conformation. Phosphorylation of key tyrosines in the juxtamembrane 
region destabilizes these autoinhibitory interactions and allows the TKD to 
assume an active conformation.
Tie2-like (C-terminal tail inhibition). In Tie2 (and possibly Met and Ron), the 
C-terminal tail (red) interacts with the active site of the TKD to stabilize an 
inactive conformation (Shewchuk et al., 2000).
(F) The EGFR TKD is allosterically activated by direct contacts between the 
C-lobe of one TKD, the “Activator,” and the N-lobe of another TKD, “Receiver” 
(Zhang et al., 2006). The Activator TKD destabilizes autoinhibitory interac-
tions that involve the activation loop of the Receiver TKD. No activation loop 
phosphorylation is required in this mechanism (Jura et al., 2009; Red Brewer 
et al., 2009).
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appears to provide the entire dimer interface of TrkA, with the 
caveat that a 30 amino acid juxtamembrane region is miss-
ing from the most complete TrkA structure (Wehrman et al., 
2007).
KIT: A Ligand-Mediated Dimer with Receptor Contacts 
(Figure 2B)
The KIT ligand, stem cell factor (or SCF), is a homodimer of two 
four-helix bundles. Each SCF molecule binds to one molecule of 
KIT through contacts with the first three (of five) Ig-like domains 
in the KIT extracellular region (Liu et al., 2007; Yuzawa et al., 
2007). This D1-D3 region is structurally unaltered upon ligand 
binding, and association with the SCF dimer simply “crosslinks” 
the two receptors. However, the two Ig-like domains closest to 
the plasma membrane (D4 and D5) undergo a significant reori-
entation upon KIT dimerization (Yuzawa et al., 2007). D4 and 
D5 make important homotypic interactions across the dimer 
interface (Figure 2B), which properly orient the two KIT mol-
ecules for activation. Oncogenic gain-of-function mutations 
are found in the D5 domain of KIT and are thought to stabilize 
these activating interactions.
A recent study of the CSF-1 (colony stimulating factor-1) 
receptor suggests that it has an activated structure similar to 
that of KIT (Figure 2B). However, this work also indicated that 
receptor-receptor interactions are required for dimerization 
in this case (Chen et al., 2008). Additional variations on this 
theme are likely for other RTKs. For example, direct interac-
tions between membrane-proximal portions of Eph receptors 
appear to be important for their oligomerization and activation 
(Seiradake et al., 2010).
FGFR: Multiple Contacts with FGF and Heparin 
 Molecules (Figure 2C)
Dimerization of fibroblast growth factor receptors (FGFRs) uses 
a combination of bivalent ligand binding, direct receptor-recep-
tor contacts, and the involvement of an accessory molecule 
(Schlessinger et al., 2000; Stauber et al., 2000). The extracel-
lular regions of FGFRs contain three Ig-like domains (D1–D3). 
Domains D2 and D3, plus an intervening linker, are crucial for 
binding to FGF ligands (Plotnikov et al., 1999), which are mono-
meric (unlike NGF and SCF). An X-ray crystal structure of a 
dimeric complex containing the FGFR1c extracellular region, 
FGF2, and heparin in a 2:2:2 ratio (Schlessinger et al., 2000) 
showed that each receptor molecule simultaneously contacts 
both FGF and heparin (the accessory molecule). Each FGF mol-
ecule also contacts both receptor molecules in the dimer, form-
ing a major interaction with one and a more minor interaction 
with the other. Heparin simultaneously contacts both ligands in 
the dimer and both receptor molecules (through domain D2). 
Moreover, the two receptors interact directly with each other 
through their D2 domains. Thus, receptor-ligand, receptor-
heparin, ligand-heparin, and receptor-receptor interactions all 
cooperate to stabilize the FGFR dimer. Although several struc-
tures of FGF/FGFR display this type of arrangement (Ibrahimi 
et al., 2005; Plotnikov et al., 1999; Schlessinger et al., 2000; 
Stauber et al., 2000), an alternative configuration has also been 
observed in X-ray crystal structures, in which heparin bridges 
two FGF/FGFR complexes. This creates an asymmetric dimer 
without significant contribution of protein-protein interactions 
to the dimer interface (Pellegrini et al., 2000). Detailed analy-
ses of both engineered and disease-related mutations in FGFR 
support the physiological relevance of the symmetric arrange-
ment shown in Figure 2C rather than this alternative heparin-
bridged dimer (Ibrahimi et al., 2005).
FGFR has an additional intramolecular control mechanism 
that involves “autoinhibition” of ligand binding. The affinity of 
FGFRs for FGFs or HSPGs (heparan sulfate proteoglycans) is 
increased when either D1 or an eight residue “acid box” in the 
D1-D2 linker (Figure 1) is removed. An intramolecular interac-
tion between D1 and the ligand-binding site formed by D2 and 
D3 competes with ligand binding to FGFR. At the same time, 
the acid box binds to a positively charged “canyon” within the 
same receptor that would otherwise accommodate HSPGs/
heparin (Plotnikov et al., 1999; Schlessinger et al., 2000; Stau-
ber et al., 2000). FGFR monomers adopt a “closed” or autoin-
hibited configuration when D1 and the acid box occupy their 
intramolecular binding sites. This autoinhibited state is thought 
to be in equilibrium with an “open” configuration in which the 
two binding sites are empty and are poised to interact with FGF 
and HSPGs, allowing FGFR activation.
The EGFR/ErbB Family: The “Receptor-Mediated” 
Extreme (Figure 2D)
Receptors in the epidermal growth factor receptor (EGFR or 
ErbB) family represent the other extreme of activation mecha-
nisms, where activating ligands make no direct contribution 
to the dimerization interface. These receptors also display a 
dramatic form of intramolecular autoinhibition (Burgess et al., 
2003). The extracellular regions of ErbB receptors contain four 
domains (I–IV). Domains I and III are each ?160 amino acids 
in length, comprise β helix LRR-like “solenoid” domains, and 
both bind to activating ligands. Domains II and IV are cysteine-
rich domains consisting of ?150 amino acids each. Structures 
of the EGFR extracellular region revealed that dimerization is 
entirely “receptor mediated,” as depicted in Figure 2D (Garrett 
et al., 2002; Ogiso et al., 2002). Although the ligand is bivalent 
like those discussed above, in this case it contacts two distinct 
sites within a single receptor molecule (on domains I and III) 
rather than crosslinking two separate receptor molecules as 
seen for NGF, SCF, or FGF. This bivalent ligand binding pro-
motes substantial conformational changes in the extracellular 
region of EGFR, which unmask a dimerization arm in domain 
II (Burgess et al., 2003). Before ligand binds, this arm is com-
pletely buried by intramolecular interactions with domain IV 
that stabilize a “tethered” conformation in which both ligand 
binding and dimerization are autoinhibited (Bouyain et al., 
2005; Burgess et al., 2003; Cho and Leahy, 2002; Ferguson 
et al., 2003). Ligand binding breaks the tether, allowing the 
dimerization arm of domain II to interact with a second ligand-
bound receptor molecule (Figure 2D). As with KIT (Figure 2B), 
the membrane-proximal domain of EGFR (domain IV) also 
appears to make contacts across the dimer interface (Burgess 
et al., 2003), which may orient the dimers in the configuration 
required for maximal activation.
New Lessons from Other RTKs
Although many of the 58 RTKs in humans are likely to use one 
of the four mechanisms outlined above for activation, further 
studies will certainly identify new variations. For example, the 
two human discoidin domain receptors (DDR1 and DDR2) are 
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activated by collagen fibers rather than soluble growth fac-
tors (Shrivastava et al., 1997; Vogel et al., 1997). Little is known 
about how collagen binding promotes receptor dimerization 
and activation. The kinetics of DDR1/2 activation is unusually 
slow, suggesting that these receptors may reveal a new twist 
on the theme of receptor crosslinking by multivalent ligands.
The Ryk (related to receptor tyrosine kinase), Ror (RTK-like 
orphan receptor), and MuSK (muscle-specific kinase) families 
of RTKs, which all have unexpected links to Wnt signaling (van 
Amerongen et al., 2008), probably also use a unique activa-
tion mechanism. Ryk contains a Wnt-inhibitory factor-1 (WIF-1) 
domain in its extracellular region and is reported to function as 
a receptor (or coreceptor) for Wnts. However, the mechanistic 
details remain poorly defined, and it is not clear whether Ryk 
contains an active tyrosine kinase domain. The two Ror RTKs 
also appear to bind Wnts through a domain in their extracellular 
regions that is closely related to the cysteine-rich Wnt-binding 
domain found in the Frizzled receptors. Moreover, Ror2 appears 
to mediate certain responses to Wnt5a (van Amerongen et al., 
2008). The MuSK RTK also has a cysteine-rich domain related 
to Frizzled receptors (Figure 1), suggesting a Wnt connection. 
MuSK is regulated by the HSPG agrin, but efforts to detect 
direct interactions between agrin and the MuSK extracellular 
region have been unsuccessful (Stiegler et al., 2006). Recent 
studies showed that Lrp4 (LDL receptor-related protein 4) 
functions as an accessory molecule for MuSK; it binds to agrin 
and mediates its effects on MuSK activity (Kim et al., 2008). 
Although not yet visualized structurally, such indirect effects 
of activating ligands on RTKs are likely to represent another 
paradigm in RTK activation mechanisms.
The Ret (rearranged during transfection) receptor is also 
activated indirectly and may use a mechanism related to that 
of MuSK. Ret responds to homodimeric ligands in the glial-
derived neurotrophic factor (GDNF) family, but these ligands 
must first bind to a GDNF-family receptor-α (GFRα) chain 
(Runeberg-Roos and Saarma, 2007) that is glycosyl phosphati-
dylinositol (GPI) anchored. The GFRα/GDNF complex appears 
to promote dimerization of Ret, and the steps in this process 
have been identified by quantitative studies in a cellular con-
text (Schlee et al., 2006). Ret illustrates another variation on the 
ligand-mediated dimerization theme and may also provide a 
model for understanding how agrin/Lrp4 complexes promote 
MuSK dimerization.
Activation of Intracellular Kinase Domains
The crucial question of how ligand-induced dimerization of the 
extracellular regions of RTKs leads to activation of the intra-
cellular tyrosine kinase domain (TKD) has been addressed in 
detail for several RTKs, including KIT, FGFR, the insulin recep-
tor, and EGFR. The activation mechanisms are surprisingly dif-
ferent. All TKDs have an N-lobe and a C-lobe (Figure 2E), and 
crystal structures of the activated forms of TKDs of RTKs (and 
indeed of activated TKDs in general) are all very similar (Huse 
and Kuriyan, 2002). Key regulatory elements including the 
“activation loop” and the αC helix in the kinase N-lobe adopt a 
specific configuration in all activated TKDs that is required for 
catalysis of phosphotransfer (Nolen et al., 2004). By contrast, 
the structures of inactive TKDs differ substantially from recep-
tor to receptor, and this variation reflects the diversity in their 
regulatory mechanisms. Each TKD is uniquely cis-autoinhibited 
by a set of intramolecular interactions specific for its receptor. 
Release of cis-autoinhibition, following ligand-induced recep-
tor dimerization, is the key event that triggers RTK activation.
TKD Autoinhibition by the Activation Loop: Insulin and 
FGF Receptors
A structure of the insulin receptor TKD was the first to illustrate 
RTK autoinhibition (Hubbard, 2004). A key tyrosine (Y1162) in 
the activation loop of the insulin receptor TKD projects into the 
active site as if poised to be autophosphorylated by its own 
kinase domain (i.e., in cis) (“Insulin receptor” in Figure 2E). 
This interaction stabilizes an activation loop configuration that 
occludes the active site, blocking access of both ATP and pro-
tein substrates. Thus, the insulin receptor TKD is autoinhibited 
in cis by its own activation loop. When insulin activates the 
receptor, Y1162 in one TKD within the dimer becomes phospho-
rylated by its partner (together with two additional tyrosines), 
and this trans-phosphorylation disrupts the cis-autoinhibitory 
interactions. The phosphorylated activation loop of the insu-
lin receptor TKD is then free to adopt the “active” configura-
tion seen in all other activated TKDs (Huse and Kuriyan, 2002; 
Nolen et al., 2004). The αC helix in the N-lobe also reorients, 
enabling it to contribute to stabilization of the ATP-binding site. 
Thus, “release” of cis-autoinhibition via autophosphorylation 
allows the TKD of the insulin receptor to “relax” into an active 
state (Figure 2E).
FGFR1 uses a conceptually similar mechanism, although its 
autoinhibition involves a different set of activation loop interac-
tions than does the insulin receptor (Mohammadi et al., 1996). 
Tyrosines in the activation loop of FGFR1 do not block the sub-
strate-binding site directly. Instead, they participate in a unique 
set of intramolecular contacts that stabilize the inactive confor-
mation of the kinase, in turn cis-autoinhibiting the FGFR1 TKD 
by occluding the protein-substrate-binding site but not the 
ATP-binding site. When FGF induces dimerization of its recep-
tor, trans-phosphorylation of tyrosines in the activation loop 
disrupts the cis-autoinhibitory configuration so that both the 
activation loop and the αC helix can adopt the characteristic 
active configuration (Bae et al., 2009; Chen et al., 2007).
Juxtamembrane Autoinhibition
Phosphorylation of the activation loop plays a crucial regula-
tory role in most kinases. It is required both to stabilize the 
activated configuration (Nolen et al., 2004) and to destabilize 
cis-autoinhibitory interactions. In addition to this mechanism 
of regulation, many RTKs are cis-autoinhibited by elements 
outside the TKD itself. The best known example is “juxtamem-
brane autoinhibition,” exemplified by MuSK (Till et al., 2002), 
Flt3 (Griffith et al., 2004), KIT (Mol et al., 2004), and Eph family 
RTKs (Wybenga-Groot et al., 2001). In each case, sequences in 
the juxtamembrane region make extensive contacts with sev-
eral parts of the TKD, including the activation loop, and stabi-
lize an autoinhibited conformation (“KIT” in Figure 2E). These 
autoinhibitory interactions differ in detail among the TKDs, but 
in all cases they involve key tyrosines in the juxtamembrane 
region. Receptor dimerization promotes trans-phosphorylation 
of these tyrosines, which disrupts the cis-autoinhibitory inter-
actions and promotes receptor activation (Hubbard, 2004). 
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Mutations that disrupt the autoinhibitory juxtamembrane inter-
actions in the KIT/PDGFR family constitutively activate these 
RTKs and are frequently found in cancers (Dibb et al., 2004).
Autoinhibition by C-Terminal Sequences
Another variation on this theme is seen with Tie2. Although 
the activation loop of its TKD exists in an active-like confor-
mation even without phosphorylation (Shewchuk et al., 2000), 
the nucleotide-binding loop of Tie2 adopts an inactive configu-
ration. Moreover, a region in the C-terminal tail that contains 
tyrosine autophosphorylation sites blocks substrate access to 
the active site, representing a third form of reversible cis-auto-
inhibition (Niu et al., 2002) generalized in Figure 2E (“Tie2”). 
Autophosphorylation of the Tie2 C-terminal tail may disrupt 
these autoinhibitory interactions (and thus activate Tie2) in a 
manner similar to reversal of juxtamembrane autoinhibition. A 
similar situation may also exist for PDGFR and Ron, although 
structural details have yet to be described.
Allosteric Activation of TKDs
For all of the TKDs discussed above, activation requires 
trans-phosphorylation of tyrosines in the activation loop, the 
juxtamembrane segment, and/or the C-terminal region. How-
ever, even when autoinhibited, the TKD is thought to have suf-
ficient kinase activity to trans-phosphorylate its partner in an 
RTK dimer stabilized by ligand binding. The cis-autoinhibitory 
interactions outlined above are thought to “breathe,” such that 
each TKD is, for a portion of the time, both competent to phos-
phorylate its neighbor and susceptible to phosphorylation at 
key regulatory sites. Bringing two TKDs together in a specific 
stable dimer increases their respective local concentrations 
and may also promote allosteric effects. These influences 
dramatically increase the probability that a transiently active 
TKD will encounter another TKD that can be phosphorylated 
in a way that promotes activation. Trans-autophosphorylation 
ensues, and the receptors become activated.
The EGFR/ErbB family and Ret stand out as clear exceptions 
to this rule because they do not require trans-phosphorylation of 
their activation loops (or elsewhere) for activation (Knowles et al., 
2006; Zhang et al., 2006). How, then, are these RTKs regulated? 
Ret activation may involve disruption of trans-autoinhibitory 
interactions that were seen in crystallographic dimers of its TKD 
(Knowles et al., 2006). For EGFR, crystallographic and mutational 
studies have identified an allosteric mechanism that resembles 
activation of cyclin-dependent kinases (CDKs) by cyclins (Zhang 
et al., 2006). The EGFR TKD forms an asymmetric dimer (Figure 
2F) in which the C-lobe of one TKD, called the “Activator,” makes 
intimate contacts with the N-lobe of the second TKD, called the 
“Receiver.” These contacts induce conformational changes in the 
N-lobe of the Receiver kinase that disrupt cis-autoinhibitory inter-
actions seen in the monomer. As a result, the Receiver kinase can 
adopt the characteristic active configuration without phosphory-
lation of its activation loop. EGFR can also be activated without 
ligand binding when the monomer’s cis-autoinhibitory interac-
tions are disrupted by oncogenic mutations found in a subset of 
patients with non-small cell lung cancer (NSCLC) (Sharma et al., 
2007). ErbB4 is regulated through a similar mechanism as seen 
for EGFR (Qiu  et al., 2008), and mutations in the asymmetric TKD 
dimer interface of EGFR or ErbB4 impair normal activation of the 
intact receptors (Qiu et al., 2008; Zhang et al., 2006).
Recent studies show that the intracellular juxtamembrane 
region of EGFR also plays a key part in promoting the allosteric 
mechanism of its activation (Jura et al., 2009; Red Brewer et 
al., 2009), instead of serving the autoinhibitory role described 
above for juxtamembrane regions of several other RTKs. Part 
of the juxtamembrane region of the Receiver kinase “cradles” 
the C-lobe of the Activator kinase in the dimer represented in 
Figure 2F. This interaction promotes dimerization and, thus, 
allosteric activation of the Receiver. The remainder of the 
Receiver’s juxtamembrane region may interact with its coun-
terpart in the Activator to further stabilize the asymmetric dimer 
(Jura et al., 2009). Certain mutations in lung cancer appear to 
promote EGFR activation by stabilizing these juxtamembrane 
interactions (Red Brewer et al., 2009).
Interestingly, Jura et al. (2009) also identified a structure of a 
potential inactive dimer for the EGFR TKD, in which C-terminal 
sequences occlude the site on the Activator onto which the 
Receiver juxtamembrane region must dock for receptor activa-
tion. This supports an autoinhibitory role for the EGFR C ter-
minus, as suggested previously (Walton et al., 1990). Studies 
of intact EGFR also argue that the juxtamembrane region is 
involved in allosteric control of ligand binding by the recep-
tor (Macdonald-Obermann and Pike, 2009). Clearly, many 
important lessons still remain to be learned about the details 
of EGFR activation.
Linking RTK Activation to Cell Signaling
The first and primary substrates that RTKs phosphorylate are 
the receptors themselves. Autophosphorylation sites in the 
kinase domain itself play an important regulatory role in most 
RTKs, with EGFR and Ret as exceptions. Autophosphorylation 
of the activation loop in the insulin receptor TKD increases its 
catalytic efficiency by 50- to 200-fold (Cobb et al., 1989). Addi-
tional tyrosines are then autophosphorylated in other parts of 
the cytoplasmic region of most RTKs (IRS proteins fulfill this 
function for the insulin receptor). The resulting phosphoty-
rosines function as specific sites for the assembly of down-
stream signaling molecules that are recruited to the receptor 
and activated in response to growth factor stimulation.
Phases of RTK Autophosphorylation
Studies of several RTKs in vitro demonstrated that auto-
phosphorylation occurs in trans (Favelyukis et al., 2001; 
Furdui et al., 2006; Honegger et al., 1989; Till et al., 2002) 
and that autophosphorylation sites are phosphorylated in 
a precise order. For example, in the closely related insulin 
receptor and IGF1 receptor tyrosine kinases, the three sites 
in the activation loop are phosphorylated in the same order: 
Y1162, Y1158, and then Y1163 (using insulin receptor num-
bering) (Favelyukis et al., 2001). Each successive event has 
a significant effect on catalytic properties by destabilizing 
the cis-autoinhibitory interactions outlined above. The first 
phosphorylation event causes the largest increase in Vmax; 
the second event causes the largest drop in KM for sub-
strates (Favelyukis et al., 2001); and the third event has a 
modest effect on both. In the case of MuSK, phosphoryla-
tion of Y553 in the autoinhibitory juxtamembrane region and 
Y754 in the activation loop precede two additional phospho-
rylation events in the activation loop (Till et al., 2002). These 
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are “first-phase” autophosphorylation events that primarily 
serve to enhance the catalytic activity of the kinase once the 
receptor binds its activating ligand.
Autophosphorylation events in a “second phase” require 
prior (first phase) activation of the kinase and create the 
phosphotyrosine-based binding sites that recruit cytoplas-
mic signaling molecules containing Src homology-2 (SH2) 
and phosphotyrosine-binding (PTB) domains. Recent studies 
indicate that a third phase also exists for some RTKs, involv-
ing trans-autophosphorylation events that maximize the ability 
of the kinase to phosphorylate its downstream targets. Stud-
ies with FGFR1 showed that autophosphorylation of Y653 in 
the activation loop, which increases kinase activity by ?10- to 
50-fold, is the key autophosphorylation event during the first 
phase (Furdui et al., 2006). Second-phase autophosphoryla-
tion events then occur in an unexpectedly precise order. Y583, 
which lies in an extra loop within the TKD called the kinase 
insert, is trans-autophosphorylated first. Y463 in the jux-
tamembrane region is phosphorylated next and is followed by 
Y585 in the kinase insert. These three second-phase sites are 
likely to be SH2/PTB domain docking sites, and their phos-
phorylation promotes recruitment of downstream signaling 
molecules rather than increasing kinase activity. After this sec-
ond phase, a further autophosphorylation event occurs in the 
FGFR1 activation loop (at Y654) that elevates kinase activity an 
additional 10-fold (Furdui et al., 2006) to reach 100–500 times 
basal levels. This modification of Y654 represents a “third 
phase” of autophosphorylation that maximally stimulates the 
FGFR1 kinase domain for phosphorylation of downstream tar-
gets such as phospholipase C-γ (PLCγ) and the FGF receptor 
substrate-2 (FRS2). Phosphorylation of Y654 is not needed for 
receptor autophosphorylation events in the second phase that 
direct the assembly of signaling molecules on the activated 
receptor.
Receptor Activation Nucleates Formation of Signaling 
Complexes
The first response to autophosphorylation of RTKs is the recruit-
ment and activation of a host of downstream signaling mole-
cules. These molecules contain SH2 or PTB domains that spe-
cifically bind to phosphotyrosine (Pawson, 2004; Schlessinger 
and Lemmon, 2003). They may be directly recruited to phos-
photyrosines in the receptor, or they may be recruited indirectly 
by binding to docking proteins that are phosphorylated by RTKs 
with which they associate (Schlessinger, 2000). These docking 
proteins include FRS2, IRS1 (insulin receptor substrate-1), and 
Gab1 (the Grb2-associated binder). Phosphorylation of docking 
proteins is functionally equivalent to second-phase RTK auto-
phosphorylation. Docking proteins typically contain a mem-
brane targeting site at their amino (N) terminus, followed by an 
array of tyrosine phosphorylation sites that serve as binding 
sites for a distinct repertoire of downstream signaling proteins 
(Figure 3A). Although a number of docking proteins (such as 
Gab1) are recruited by multiple RTKs, others are restricted to 
particular subsets of receptors. For example, the two mem-
bers of the FRS2 family (FRS2α and FRS2β) mediate signaling 
primarily by FGF and NGF receptors (Schlessinger, 2000). The 
four members of the IRS family (IRS1–4) play crucial roles in 
mediating signaling by the insulin and IGF1 receptors, which 
rely entirely on these docking proteins for recruitment of down-
stream signaling molecules. With multiple phosphotyrosines 
in most receptors and the involvement of numerous docking 
proteins, activated RTKs clearly can recruit and influence a 
large number of different signaling molecules. Therefore, an 
activated RTK can be thought of as a node in a complex signal-
ing network that transmits information from the exterior to the 
interior of the cell.
Figure 3. Coincidence Detection and Network Branching in RTK 
Signaling
(A) Coordinated assembly of multiprotein complexes in receptor tyrosine ki-
nase (RTK) signaling provides branching points in a signaling network. The 
docking protein FGF receptor substrate-2 (FRS2α) forms a complex with ac-
tivated fibroblast growth factor (FGF) or nerve growth factor (NGF) receptors 
via its phosphotyrosine-binding domain (PTB). The activated RTK phosphory-
lates FRS2α on multiple tyrosines, and the resulting phosphotyrosines recruit 
multiple Grb2 and Shp2 molecules, which bring a second docking protein, 
Gab1, into the complex. Gab1 is tyrosine phosphorylated and recruits ad-
ditional signaling proteins, including phosphoinositide 3-kinase (PI-3K). PI-3K 
initiates a positive feedback loop in which PtdIns(3,4,5)P3 (PIP3), generated by 
PI-3K, recruits more Gab1, leading to further PI-3K activation. 
(B) The multiple domains of phospholipase C-γ (PLCγ) cooperate to integrate 
multiple signals at the plasma membrane. The N-terminal SH2 domain is 
responsible for complex formation with activated receptor tyrosine kinases 
(RTKs). The C2 and PH domains cooperate with the SH2 domain to target 
PLCγ to the plasma membrane. One or both of the PH domains may also spe-
cifically recognize products of RTK-activated PI-3K. RTK-mediated tyrosine 
phosphorylation of PLCγ leads to intramolecular binding of the C-terminal 
SH2 domain to phosphotyrosine 783. This stimulates enzymatic activity of 
PLCγ, leading to hydrolysis of PtdIns(4,5)P2 (PIP2), and consequently leads to 
the formation of Ins(1,4,5)P3 (IP3) and diacylglycerol (DAG).
1124 Cell 141, June 25, 2010 ©2010 Elsevier Inc.
Multidomain Interactions Specify Signaling Complex 
Formation
It is now well appreciated that a wide array of interaction mod-
ules is responsible for communication among signaling mol-
ecules in the networks influenced by RTKs (Seet et al., 2006). 
These signaling molecules frequently contain multiple mod-
ules, as illustrated in Figure 3B for PLCγ. Table S2 (available 
in the Supplemental Information online) depicts various pro-
tein modules known to mediate intermolecular interactions in 
RTK signaling networks. Some modules bind RTKs directly in 
“receptor-proximal” interactions (e.g., SH2, PTB), whereas oth-
ers are involved in interactions that are spatially and temporally 
more distal. The receptor-proximal interactions require modi-
fication of the receptor. SH2 and PTB domains bind only to 
the tyrosine-phosphorylated receptor (with a few exceptions) 
and subsequently link RTK autophosphorylation to the initia-
tion of other events in the signaling network (Pawson, 2004; 
Schlessinger and Lemmon, 2003). Several ubiquitin-binding 
modules (Hurley et al., 2006) also bind directly to RTKs that 
have been ubiquitylated. Ubiquitylation, which frequently 
depends on receptor activation, directs termination of the 
RTK’s influence on the signaling network by promoting recep-
tor degradation (Kirkin and Dikic, 2007), creating an important 
negative feedback mechanism (Hunter, 2007). The remaining 
modules listed and defined in Table S2 fall into two categories. 
SH3, WW, and PDZ domains are all examples of protein-pro-
tein interaction modules, whereas PH (pleckstrin homology), 
PX, C1, C2, and FYVE domains are all best known as phospho-
lipid-binding modules. Domains in these classes are frequently 
located alongside SH2 domains in the typical multidomain pro-
teins that signal downstream of RTKs (Figure 3B).
Although these domains certainly drive and specify the for-
mation of key signaling complexes (reviewed by Seet et al., 
2006), few of these modules show sufficient binding selectiv-
ity or affinity on their own to explain the precise specificity of 
signaling-complex formation (Ladbury and Arold, 2000). Mul-
tivalency appears to be a key solution, with several domains 
in a single signaling protein cooperating with one another to 
drive formation of the signaling complex (or network node) in 
response to several cues (Pawson, 2004; Seet et al., 2006). The 
example of PLCγ illustrates this point nicely (Figure 3B). Two 
SH2 domains, two PH domains (one split into two parts), one 
C2 domain, and one SH3 domain all participate in multivalent 
signal-dependent targeting of PLCγ to its site of action at the 
membrane. The SH2 domains bind phosphotyrosines in the 
receptor or docking protein; the PH domains bind phospho-
inositides at the plasma membrane, including the PI 3-kinase 
product PtdIns(3,4,5)P3; the C2 domain also binds membrane 
components; and the SH3 domain binds Cbl (Casitas B-lineage 
lymphoma) that has been recruited into the signaling complex 
(Tvorogov and Carpenter, 2002). PLCγ thus integrates multi-
ple signal inputs through a combination of recognition mod-
ules, which permits “coincidence detection” (Pawson, 2007). 
Another example involves tandem SH2 domains that engage 
their target receptor only if two tyrosines in the target are phos-
phorylated such that both SH2 domains can bind simultane-
ously (Eck et al., 1996). Indeed, the phosphotyrosines in RTKs 
that bind to downstream signaling molecules with tandem SH2 
domains (e.g., PLCγ, ZAP-70, PI-3 kinase [PI-3K], and Shp 
phosphatases) have been the easiest sites to map, implying a 
stricter specificity in these multivalent cases.
New Perspectives on Well-Known Signaling Domains
It has long been thought that the determinants of specificity in 
SH2 domain interactions with their target proteins are limited 
largely to the primary sequence surrounding the phosphoty-
rosine (Songyang and Cantley, 2004). Structural details of SH2 
domains recognizing short phosphopeptides, which are well 
described elsewhere (Waksman and Kuriyan, 2004), reinforced 
this hypothesis by explaining the results of in vitro studies of 
peptide-binding specificity. The assumption that all cellular 
SH2 domain-mediated interactions can be recapitulated using 
short phosphopeptides has prompted their use in protein 
microarray studies to generate quantitative potential interac-
tion networks for certain RTKs. Although the resulting network 
for EGFR (Jones et al., 2006), for example, contained many of 
the SH2 domain-mediated interactions already known for this 
receptor, it also predicted a larger number of interactions not 
identified in prior studies with intact EGFR. It is tempting to 
assume that many such interactions were simply missed in the 
earlier more targeted, lower-throughput studies of EGFR. How-
ever, it is equally possible that these additional hypothetical 
interactions are not physiologically relevant and arise because 
comparative microarray-based binding studies were under-
taken with short peptides rather than the intact proteins.
Recent structural studies with SH2 domains provide impor-
tant insights into this issue and suggest that studies with short 
peptides may indeed miss crucial specificity determinants. 
Bae et al. (2009) reported the first structure of an SH2 domain 
from an RTK substrate bound to a phosphorylated RTK rather 
than to a phosphopeptide. A fragment of PLCγ1 containing both 
SH2 domains was crystallized in complex with the phosphory-
lated FGFR1 intracellular domain. Although the two PLCγ1 SH2 
domains bind with similar affinities to phosphopeptides corre-
sponding to FGFR1 pY766, the N-terminal SH2 domain binds 
>15 times more strongly than the C-terminal SH2 to the phos-
phorylated FGFR1 intracellular domain (Bae et al., 2009). The 
dissociation constant (KD) for the PLCγ1 N-terminal SH2 domain 
binding to the phosphorylated FGFR1 intracellular domain is 33 
nM, compared with the more “normal” KD value of more than 
one micromolar for its binding to phosphopeptides. Crystallog-
raphy and mutagenesis studies showed that the enhanced affin-
ity results from a secondary binding site on the N-terminal PLCγ1 
SH2 domain that contacts key regions in the C-lobe of the FGFR1 
kinase domain. In addition to the canonical “two-pronged plug” 
binding mode seen in studies of SH2 domain/phosphopeptide 
complexes (Waksman and Kuriyan, 2004), the N-terminal PLCγ1 
SH2 domain uses a separate specificity-determining site that 
buries almost the same surface area and is crucial for FGFR1-
mediated PLCγ1 activation in cells. It will be very important to 
determine whether or not the case of the PLCγ N-terminal SH2 
domain is typical for cellular SH2 domain interactions. This will 
require extensive future studies of SH2 domain binding to intact 
protein partners rather than to peptide mimetics.
It is important to note that a similar situation was described 
for SH3 domains, which are best known for binding, albeit 
weakly, to peptides that contain PxxP motifs (Li, 2005). The 
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SH3 domains of p47phox and Src family kinases bind a great 
deal more strongly to their respective intact protein partners 
than to PxxP-containing peptides. In doing so, they “augment” 
the canonical PxxP-binding modes with additional contacts 
that increase affinity and specificity for the intact protein (Li, 
2005). Although the key experiments have yet to be performed 
for many of the other domains, these views of SH2 and SH3 
binding to their intact protein targets argue that short synthetic 
peptides do not represent good mimetics of the physiologi-
cal interactions that define signaling pathways. Understanding 
the full spectrum of specificity determinants will be crucial for 
future systems-level analysis of signaling networks.
RTKs as Nodes in Complex Signaling Networks
As the first SH2 domain-containing proteins, Ras exchange 
factors, MAP kinases, and other proteins involved in RTK 
signaling were being identified, the prevailing view was that 
these components comprise linear signaling pathways. A key 
example that appeared to support this hypothesis was the 
RTK-Grb2-Sos-Ras/MAP kinase pathway. Genetic experi-
ments further supported this linear-pathway view (Noselli and 
Perrimon, 2000). However, several key emerging facts clearly 
suggested that a more complicated and intertwined signaling 
network must exist for RTKs. First, RTKs such as EGFR have 
multiple (5–12) autophosphorylation sites that can each recruit 
different SH2 and PTB domain-containing proteins; second, a 
given adaptor or scaffold protein can interact with multiple sig-
naling molecules (Pawson, 1995; Schlessinger, 2000). More-
over, as biochemical analyses advanced, it became clear that 
all pathways previously thought to be linear are in fact highly 
interconnected into a complex and dynamic signaling network 
(Figure 4A), with RTKs functioning as key regulatory nodes. An 
important conundrum arose as different RTKs that elicit quite 
distinct cellular responses (e.g., proliferation versus differen-
tiation) were shown nonetheless to engage overlapping and 
similar complements of receptor-proximal components in the 
cellular signaling network. If both the EGF and NGF receptors 
activate similar sets of RTK-proximal downstream signaling 
molecules, how can activating the EGFR lead to cell prolifera-
tion whereas activating the NGF receptor promotes neurite 
outgrowth and differentiation in the same cell (Marshall, 1995)? 
In other words, what defines the specificity of signaling?
Simply knowing the components of a signaling pathway or 
network is not sufficient to predict qualitative outcomes of its 
activation. Neither is it sufficient to know the components of the 
RTK signaling node. Instead, a quantitative understanding of 
how the network behaves as a whole is crucial. Experimentally, 
this fact is underscored by very early experiments showing that 
activation of a given RTK by its ligand has dramatically differ-
ent effects depending on the RTK’s expression level and the 
kinetics of its activation (Marshall, 1995). Indeed, the dynam-
ics and extent of network activation are critical for determining 
outcome (Kholodenko, 2006; Murphy and Blenis, 2006), but 
they are extremely difficult to intuit in a qualitative sense. For 
example, simply overexpressing EGFR or the insulin receptor 
in PC12 cells switches the outcome of stimulation with EGF 
Figure 4. Intracellular Signaling Networks Activated by EGFR
(A) A subset of intracellular signaling components influenced by epidermal growth factor receptor (EGFR) activation are intertwined in a complex network. 
Through a combination of stimulatory (black arrows) or inhibitory (red lines) signals, several key positive feedback loops (blue circular arrows) and negative 
feedback loops (red circular arrows) emerge in the network and exert significant influence on its behavior. For example, inhibition of Ras by Ras-GAP or EGFR 
by protein kinase C (PKC) serves a negative feedback function. On the other hand, H2O2 inhibits protein tyrosine phosphatases (PTPs) and thus prolongs or 
increases activity of EGFR by a positive feedback mechanism. 
(B) A conceptual representation of a “bow tie” or “hourglass” network, as described by Kitano (2004). A wide “input layer” (green) includes multiple RTKs that 
all influence a relatively small number of “core processes” (magenta), including phosphoinositide 3-kinase (PI-3K) signaling, MAPK signaling, and Ca2+ signal-
ing. Feedback processes within the core define specific emergent properties of the system. The behavior of the core processes is “read out” by a wide output 
layer (orange) that consists of diverse transcriptional responses and cytoskeletal changes. Extensive negative and positive feedback loops exist between the 
core processes and the input layer. Similar feedback exists between the output layer and the core processes, in addition to “feedforward” regulation by core 
processes (e.g., MAPK signaling) of immediate early gene products described by Murphy and Blenis (2006). An additional layer of “system control” also occurs 
between the input and output layers.
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or insulin from a proliferative response with transient MAPK 
activation (as seen in wild-type PC12 cells) to cell differentia-
tion and neurite outgrowth, with more sustained MAPK activa-
tion (Marshall, 1995). This dramatic shift in cellular response is 
partly due to the differential engagement of positive and nega-
tive feedback mechanisms (Santos et al., 2007).
Current systems-biology efforts to understand RTK signal-
ing are focused on quantitative analysis of signaling networks. 
However, this is a very daunting challenge. For example, a map 
of the signaling network influenced by the EGFR node (Oda 
et al., 2005) contains 211 reactions involving 322 components 
(a small subset of which are shown in Figure 4A). Quantita-
tive information is scant for the vast majority of these reac-
tions. Thus, full deterministic modeling is currently impos-
sible, even when spatial and stochastic aspects are ignored, 
and this is likely to be true for the foreseeable future. Readers 
are directed to recent reviews (Huang and White, 2008; Laz-
zara and Lauffenburger, 2009) for detailed discussions of the 
current challenges and opportunities in combining quantita-
tive proteomics and computational modeling approaches to 
describe ErbB receptor signaling.
Several key organizational features have emerged from 
systems views of EGFR/ErbB receptor signaling that provide 
useful insights into the structure and behavior of the underly-
ing networks. One key concept is the “bow-tie” or “hourglass” 
structure of the network (Citri and Yarden, 2006; Oda et al., 
2005), where diverse inputs and outputs are linked through a 
conserved “processing” core (Figure 4B). The four ErbB recep-
tors (EGFR, ErbB2, ErbB3, and ErbB4) are regulated by multiple 
ligands to yield a broad array of signaling inputs into the net-
work. These inputs (and those from other RTKs) converge on a 
relatively limited set of highly conserved “core processes” (Fig-
ure 4B), mirroring the initial impression that a surprisingly small 
group of downstream signaling intermediates propagate sig-
nals from all RTKs. The bow tie or hourglass then widens again 
as the core processes are linked to the control of transcrip-
tional, cytoskeletal, and other “output” events that define the 
cellular response (e.g., proliferation, differentiation, apoptosis). 
Several of the core processes are shown in Figure 4A, includ-
ing small GTPase cycles, kinase cascades, phosphoinositide 
signaling, nonreceptor tyrosine kinase activities, and ubiquity-
lation/deubiquitylation cycles. There is significant redundancy 
and substantial crosstalk between the subnetworks or mod-
ules that constitute the conserved core processes, and this 
has been noted as a characteristic feature of robust and evolv-
able systems (Kitano, 2004).
Unfortunately, even details of the input level of the bow tie 
network remain poorly understood, making deterministic mod-
eling of the system impossible at present. It is still not clear 
exactly how EGFR itself is activated. Neither is it clear which 
ErbB receptors are activated by each of the several ErbB 
ligands (and to what extent), how ErbB receptors heterodi-
merize (and with what stoichiometry), or how rapidly different 
activated ErbB receptor complexes are internalized and dis-
abled. However, conceptualization of network organization has 
aided and simplified efforts to model ligand/receptor dynamics 
and has provided substantial insights (Lazzara and Lauffen-
burger, 2009). Moreover, it has become clear that positive 
and negative feedback loops, both within and between differ-
ent levels, play key roles in regulating the “information flow” 
through the bow tie network and can explain many emergent 
properties of the system (Citri and Yarden, 2006; Kholodenko, 
2006; Kitano, 2004; Oda et al., 2005).
Positive and Negative Feedback in RTK Signaling 
Networks
Figure 4A depicts selected key elements of the EGFR signal-
ing network, illustrating the substantial redundancy in the core 
processes as well as the numerous positive and negative feed-
back loops. Positive feedback increases the sensitivity of the 
system to signaling inputs by amplifying the stimulus. It can 
also lead to bistability (Kholodenko, 2006), or “switch-like” 
ligand-induced transitions between two distinct steady states, 
leading to differentiation versus proliferation for example. Neg-
ative feedback in the network serves in part to dampen noise, 
thus preventing stochastic minor fluctuations in RTK activation 
from promoting signaling. Negative feedback in a system can 
define the steady-state level of a response, keeping it constant 
over a wide range of signaling inputs and thus imparting sub-
stantial robustness to the system (Kitano, 2004; Stelling et al., 
2004). Moreover, characteristic oscillations in the system can 
result from positive feedback loops (with substrate depletion), 
negative feedback loops, or a combination of the two types of 
feedback (Kholodenko, 2006). The nature of these oscillations 
is a characteristic property of the network, and their full under-
standing requires quantitative modeling of the system.
Positive Feedback Mechanisms
Phosphorylation/dephosphorylation cycles represent a uni-
versal motif in cell signaling (Kholodenko, 2006), and sto-
chastic RTK autophosphorylation is reversed by a variety of 
protein tyrosine phosphatases (PTPs). In principle, RTK acti-
vation can be promoted by ligand-stimulated kinase activ-
ity, ligand-inhibited PTP activity, or both. Indeed, it is well 
known that inhibiting PTPs with pharmacological agents pro-
motes general activation of RTKs in cells (Ostman and Böh-
mer, 2001). A similar reaction can occur in RTK signaling as 
a mechanism of positive feedback. Sustained activation of 
EGFR is accompanied by ligand-induced production of H2O2 
and other reactive oxygen species (ROS), mediated by PI-3K 
and Rac-dependent activation of NADPH-oxidase (Bae et al., 
1997). These ROS transiently inhibit PTP activity by oxidiz-
ing a crucial cysteine in the phosphatase active site (Tonks, 
2006). This temporary inactivation of negative regulatory pro-
teins (the PTPs) represents a positive feedback mechanism 
(Figure 4A) and constitutes a bistable switch. It has been pro-
posed that EGF-induced H2O2 production drives global acti-
vation of EGFR molecules in a cell; diffusion of H2O2 through 
the cells inhibits distant PTPs that activate unoccupied EGFR 
molecules, resulting in lateral signaling propagation (Reynolds 
et al., 2003). Significant questions remain about the range of 
this phenomenon (Schlessinger, 2002). Indeed, ROS have a 
very limited lifetime and are, therefore, likely to function as 
“messengers” over only very short distances within the cell. 
Moreover, it is not clear how such a mechanism would selec-
tively activate EGFR in preference to other phosphorylation-
dependent signals.
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Another positive feedback loop occurs at the level of Gab1 
(Figures 3A and 4A). Gab1 is recruited to activated EGFR (or 
FRS2 in FGFR signaling) via the Grb2 adaptor. Gab1 becomes 
tyrosine phosphorylated at sites that recruit the SH2 domains 
of the PI-3K p85 subunit, providing an indirect mechanism for 
EGFR (or FGFR) to activate PI-3K (Figures 3A and 4A). Gab1 
also contains an N-terminal PH domain with clear specific-
ity for PI-3K products (Gu and Neel, 2003). The PH domain, 
therefore, promotes PtdIns(3,4,5)P3-dependent translocation 
of Gab1 to the membrane in response to PI-3K activation, cre-
ating a positive feedback loop that stimulates Akt-dependent 
antiapoptotic signaling.
EGFR-dependent autocrine activation represents a third 
type of positive feedback loop. This loop is shown in Figure 4A 
as EGFR-driven activation of Shc and Src, which promotes the 
ability of ADAM family proteases to cleave membrane-bound 
heparin-binding EGF-like growth factor (HB-EGF) from the cell 
surface. The shed HB-EGF drives autocrine EGFR signaling, 
which is an important factor in several cancers (Hynes and 
Schlange, 2006). Similarly, in both mammalian and Droso-
phila systems, activation of the Ras-MAPK pathway induces 
production of EGFR/ErbB receptor ligands, providing another 
key positive feedback mechanism (Schulze et al., 2004; Shilo, 
2005).
Negative Feedback Mechanisms
Negative feedback mechanisms operate at many steps in the 
signaling networks controlled by RTKs. Direct activation of 
PTPs (as opposed to the transient ROS-dependent inhibition 
of phosphatases) represents one obvious negative feedback 
mechanism. The SH2 domain-containing phosphatases Shp1 
(PTPN6) and Shp2 (PTPN11) are recruited to activated EGFR 
and promote its dephosphorylation in a negative feedback 
loop (not shown in Figure 4A). RTK activity is also attenuated 
by negative feedback loops that result from receptor-depen-
dent stimulation of heterologous protein kinases. For example, 
EGFR stimulation promotes activation of protein kinase C 
(PKC) via PLCγ. In turn, PKC can phosphorylate T654 in the 
juxtamembrane domain of EGFR (Figure 4A). This eliminates 
high-affinity binding of EGF to cell-surface EGFR (Ullrich and 
Schlessinger, 1990) and thus inhibits EGFR activation in a neg-
ative feedback loop.
Several negative feedback mechanisms also control RTK-
mediated MAPK responses, as expected given their central 
role in the network’s core processes. As shown in Figure 4A, 
two critical upstream regulators of MAPK (Sos and Raf) are 
also direct MAPK substrates. Direct phosphorylation of Sos 
by MAPK impairs Sos/Grb2 interactions and thus reduces Sos 
recruitment to the membrane, in turn dampening Ras activa-
tion (Buday et al., 1995). In addition, MAPK phosphorylates its 
upstream regulator Raf (Ueki et al., 1994), leading to a reduc-
tion in Raf kinase activity and consequently diminished phos-
phorylation of MAPKK and MAPK. MAPK also phosphorylates 
docking proteins in another mode of negative feedback that 
links core processes to the input layer of the bow tie (Figure 
4B). MAPK activation leads to Gab1 phosphorylation, which 
diminishes the ability of Gab1 to recruit and activate PI-3K 
(Gual et al., 2001). The IRS1 and FRS2 docking proteins are 
also phosphorylated by MAPK in similar negative feedback 
loops in insulin and FGF receptor signaling, respectively (Lax 
et al., 2002; Mothe and Van Obberghen, 1996). Moreover, MAP 
kinase inactivates the EGFR itself, by phosphorylating T669 in 
the juxtamembrane region (Li et al., 2008). Naturally, another 
key element of negative feedback in RTK signaling involves 
downregulation of the receptors following their activation. 
As discussed below, there remains significant debate about 
the molecular mechanisms that control RTK internalization 
and degradation (Sorkin and Goh, 2009; Zwang and Yarden, 
2009).
A slower negative feedback mechanism involves signal-
dependent transcription of negative regulators of the net-
work. Amit et al. (2007) identified several signal attenuators 
among the group of “delayed early gene” products induced 
by EGFR signaling with a delay of more than 40 min. These 
included several known transcriptional repressors, including 
ID2, NAB2, FOSL1, and JUNB, which attenuate EGF-driven 
transcription (including that driven by immediate early gene 
products). Several other delayed early gene products, includ-
ing Krüppel-like factors (KLF) -2 and -6, were also shown to 
repress EGF-dependent transcription events when expressed. 
Still other attenuators encoded by delayed early genes include 
the RNA-binding protein ZFP36, which may promote degrada-
tion of short-lived inducible mRNAs, and several dual-specific-
ity phosphatases (the identity of which was cell and stimulus 
specific), which feed back to attenuate MAP kinase activity in 
the network (Amit et al., 2007).
There are several other inhibitors of EGFR family signaling, 
including Sprouty, LRIG-1, Mig6, as well as Argos and Kek-
kon-1 in Drosophila (Shilo, 2005). LRIG-1, Kekkon-1, and Mig6 
appear to inhibit receptor function itself. In contrast, Argos 
sequesters activating ligand, and Sprouty has diverse effects 
on downstream signaling (Citri and Yarden, 2006; Shilo, 2005). 
EGFR signaling induces the expression of each of these inhibi-
tors, but apparently with a longer delay than the delayed early 
genes (Amit et al., 2007). This is consistent with their impor-
tance in coordinating EGFR signaling at the organismal level 
during development (Shilo, 2005).
Feedback/System Control Differences Explain Distinct 
Responses of PC12 Cells to EGF and NGF
We began this section on networks with the conundrum that 
NGF and EGF induce diametrically opposed cellular responses, 
with very different dynamics, despite engaging a broadly simi-
lar set of signaling intermediates (Marshall, 1995). Given the 
discussion above, it seems reasonable to expect that the dis-
tinct cellular responses to NGF and EGF reflect differences 
in the input layer of the network or its feedback mechanisms. 
Both appear to be true, and several mechanisms appear to be 
at play.
Using a combined computational and experimental 
approach, Bastiaens and colleagues have provided evidence 
for a difference in the topology of the MAPK network in PC12 
cells when activated by NGF and EGF (Santos et al., 2007). 
The key difference is additional positive feedback from MAPK 
to Raf when the system is activated by NGF, in contrast with 
only negative feedback loops (Figure 4A) in EGF-treated cells. 
As a result, NGF-induced activation of Raf and MAPK has 
switch-like, or bistable, properties that are required for the sus-
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tained response. Although the mechanism of this NGF-specific 
positive feedback is not yet clear, it appears to involve PKCδ 
because combined treatment of cells with EGF and a PKC 
activator could mimic NGF-induced sustained MAPK activa-
tion (and differentiation).
In addition to this change in “wiring” of the core processes, 
another key factor appears to be the ability of NGF (but not 
EGF) stimulation to promote sustained activation of Rap1, a 
Ras family member (York et al., 1998), leading to sustained 
B-Raf activation. Studies of TrkA indicate that NGF-induced 
activation of this receptor promotes the formation of a long-
lived signaling complex containing FRS2, the adaptor protein 
Crk, and the Rap-specific GEF C3G. This allows Rap1 activa-
tion by NGF to be prolonged (Kao et al., 2001), whereas Rap1 
is only transiently activated by EGFR. Both EGFR and TrkA 
activate Ras itself only transiently because of negative feed-
back by Ras-GAP activation (Figure 4A). The sustained MAPK 
activation seen specifically in response to NGF may therefore 
arise from the ability of TrkA to promote prolonged Raf-MAPK 
activation via Rap1.
Through these mechanisms and likely others, the dynamics 
of activation of the core processes in the bow tie signaling net-
work are dramatically different for NGF and EGF. Activation of 
the MAPK pathway becomes sustained (rather than transient) 
when PC12 cells are treated with NGF rather than EGF or when 
overexpressed EGFR or insulin receptor are stimulated. How, 
then, is the sustained MAPK pathway activation interpreted by 
the “output layer” to trigger differentiation rather than prolifera-
tion? A key here appears to be feedforward mechanisms (Fig-
ure 4B) between the “core” MAP kinase pathway and the out-
put layer products of the immediate early genes (Murphy and 
Blenis, 2006). Several immediate early gene products, such as 
c-Fos, are inherently unstable and are rapidly degraded. MAP 
kinase-dependent phosphorylation of c-Fos, directed by a 
DEF domain in c-Fos, stabilizes the protein and prolongs its 
existence. This appears also true for several immediate early 
gene products (Murphy and Blenis, 2006). If MAP kinase acti-
vation is transient and has waned by the time that c-fos is 
transcribed and translated, newly synthesized c-Fos will not 
be phosphorylated and will be rapidly degraded. In contrast, 
if MAP kinase activation is sufficiently sustained that signifi-
cant kinase activity remains when new c-Fos appears, then the 
nascent c-Fos will be stabilized by phosphorylation, allowing it 
to induce expression of late-response genes. Immediate early 
gene products thus appear to serve as “sensors” or “interpret-
ers” for MAP kinase signaling dynamics (Murphy and Blenis, 
2006).
Receptor Endocytosis in Downregulation and Signaling
An early and general response in the activation of all cell-sur-
face receptors, including RTKs, is receptor “downregulation.” 
This involves ligand-stimulated endocytosis of occupied recep-
tors and subsequent intracellular degradation of both ligand 
and receptor molecules (Sorkin and Goh, 2009; von Zastrow 
and Sorkin, 2007; Zwang and Yarden, 2009). Activated EGFR 
and other RTKs are internalized primarily by clathrin-mediated 
endocytosis following growth factor-induced receptor cluster-
ing in clathrin-coated pits. In addition, clathrin-independent 
endocytosis can play an important role under particular condi-
tions, such as cell stimulation with high ligand concentrations 
(Sadowski et al., 2009; Sorkin and Goh, 2009).
EGFR kinase activity is required for trafficking through mul-
tivesicular bodies (MVBs) into lysosomes where both EGF and 
EGFR are degraded (Sorkin and Goh, 2009). It has typically 
been assumed that RTK activation and cell signaling take 
place primarily at the cell surface, and that the primary role 
of endocytosis is to terminate RTK activation. However, sev-
eral studies show that activated RTKs continue to recruit and 
activate intracellular signaling pathways from within intracel-
lular vesicles following their internalization (Di Guglielmo et al., 
1994; Miaczynska et al., 2004; von Zastrow and Sorkin, 2007). 
After internalization, activated RTKs are dephosphorylated 
and ubiquitylated, and the activating ligand becomes dissoci-
ated in the lower pH environment of the endosomal lumen. The 
stage in the endocytic pathway at which these events occur 
varies with both ligand and receptor. In addition, depending 
on the specific receptor and ligand pair, RTKs may be recycled 
from endosomes to the plasma membrane or sorted for deg-
radation, which affects receptor number and thus signaling. As 
seen for the TrkA and TrkB neurotrophin receptors (Chen et al., 
2005), these types of differences can profoundly alter biologi-
cal response.
Intriguingly, it has become clear that the set of signaling 
molecules associated with an activated receptor can be sig-
nificantly different at the plasma membrane compared with 
that seen at endosomal (and other) compartments. This adds 
a key spatial dimension, not captured in Figure 4A, to what 
is required to understand signaling networks. For example, 
one recent study found that clathrin-mediated endocytosis is 
required for Akt and MAPK activation by EGFR (presumably in 
endosomes) but not for Shc phosphorylation. The authors also 
suggested that clathrin-mediated endocytosis prolongs the 
duration of EGFR signaling by directing the receptor toward 
a recycling fate, rather than a degradative one (Sigismund et 
al., 2008). In signaling by the RTK Met, trafficking to a peri-
nuclear endosomal compartment appears to be required for 
tyrosine phosphorylation of STAT3 and its nuclear transloca-
tion but not for MAP kinase activation (Kermorgant and Parker, 
2008). Experiments with the PDGF receptor that allow it to be 
activated in endosomes, but not at the plasma membrane, also 
support the hypothesis of signaling following internalization 
(Wang et al., 2004). Moreover, anchoring constitutively active 
forms of Flt3 in the endoplasmic reticulum diminishes activa-
tion of Akt and MAP kinase but elevates activation of STAT5 
(Choudhary et al., 2009).
These studies all demonstrate that RTKs can transmit 
intracellular signals from endosomes and other intracellular 
compartments (Miaczynska et al., 2004). They also illustrate 
that the precise subcellular location can define signaling 
specificity in a manner that is not yet understood. Certain 
RTKs, notably Eph receptors, require internalization for 
their signaling function (Sadowski et al., 2009). Understand-
ing the spatial aspects of RTK signaling in different mem-
brane compartments will, therefore, be crucial for quantita-
tive understanding and modeling of the complete network 
(Kholodenko, 2006).
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Ubiquitylation of RTKs
It is now well established that protein phosphorylation regu-
lates protein ubiquitylation and, conversely, that ubiquitylation 
regulates the function of a variety of protein kinases and phos-
phatases. Moreover, crosstalk between these two posttrans-
lational modifications plays a critical role in cell signaling by 
regulating protein degradation, processing, and cellular traf-
ficking (Hunter, 2007). One of the RTK-proximal proteins that 
associates with phosphorylated EGFR and other RTKs is Cbl. 
This E3 ubiquitin ligase is a modular oncogenic protein that 
catalyzes ubiquitylation of the cytoplasmic domains of a vari-
ety of RTKs.
Several studies have claimed that ubiquitylation serves as 
a sorting signal for targeting activated EGFR to coated pits 
for endocytosis and intracellular degradation. These studies 
also suggested that mono- (rather than poly-) ubiquitylation 
is the principal signal for EGFR endocytosis and degradation 
(Mosesson et al., 2003). More recent quantitative analyses with 
tandem mass spectrometry have shown that the EGFR cyto-
plasmic domain is polyubiquitylated for the most part (Huang 
et al., 2006). Moreover, a mutated EGFR that cannot be ubiq-
uitylated was endocytosed normally following EGF binding at 
physiological concentrations of growth factor, demonstrat-
ing that ubiquitylation is not necessary for EGFR internaliza-
tion (Huang et al., 2007). This mutated form of EGFR did show 
impaired intracellular degradation, despite being endocytosed 
efficiently (Huang et al., 2007). Similarly, deletion mutants of 
EGFR that are unable to recruit Cbl or B-Cbl (and thus fail to 
become ubiquitylated) exhibit impaired intracellular degrada-
tion and downregulation but are internalized normally (Pen-
nock and Wang, 2008). Thus, it now appears that the main role 
of ubiquitylation is to target activated EGFR for degradation 
rather than directing internalization itself. Ubiquitylation thus 
controls a crucial negative feedback element. There is much 
debate in the literature about the molecular mechanisms that 
control RTK internalization and degradation, and this topic has 
been well reviewed recently from a few different perspectives 
(Citri and Yarden, 2006; Sorkin and Goh, 2009; Zwang and 
Yarden, 2009).
RTK Mutations in Disease
It was appreciated in the 1960s that virally transformed cells 
rely less on exogenous growth factors for cell proliferation than 
their normal cell counterparts (Temin, 1966). This observation 
suggested that aberrant growth factor signaling might play a 
key role in cell transformation. Nearly two decades later, stud-
ies demonstrated that the v-sis oncogene from simian sar-
coma virus originated by viral transduction of the PDGF gene 
(Doolittle et al., 1983; Waterfield et al., 1983) and that its protein 
product (p28sis) promotes cell transformation by activating the 
PDGFR in an autocrine loop. Subsequently, the product of the 
v-erbB oncogene from avian erythroblastosis virus was found 
to correspond to a truncated and constitutively activated form 
of EGFR (Downward et al., 1984). The gene encoding EGFR 
was later shown to be amplified and mutated in primary human 
brain tumors (Libermann et al., 1985), leading to overexpres-
sion and constitutive activation of EGFR tyrosine kinase activ-
ity in tumor tissues.
Since this time, a wealth of information has accumulated 
implicating deregulated and dysfunctional RTKs in a variety of 
human diseases. Aberrant RTK activation in human cancers is 
mediated by four principal mechanisms: autocrine activation, 
chromosomal translocations, RTK overexpression, or gain-
of-function mutations. Recent sequencing efforts in a wide 
variety of tumors have identified mutations in numerous RTKs, 
collected in the COSMIC (Catalogue of Somatic Mutations in 
Cancer) database (Forbes et al., 2010). Examples in the KIT/
PDGFR, ErbB, and FGF receptor families illustrate key mecha-
nisms of tumorigenic RTK mutations.
Mutations in KIT and PDGFR Families
Gain-of-function mutations in KIT have been found in a variety 
of human cancers, including gastrointestinal-stromal tumors 
(GISTs), acute myeloid leukemia (AML), mast cell leukemia 
(MCL), and melanoma. These activating mutations cluster in 
key locations within the KIT protein (Figure S1), namely the TKD 
(exon 17), the intracellular juxtamembrane segment (exon 11), 
and exons 8 and 9 that encode D5 of the extracellular ligand-
binding region (Corless and Heinrich, 2008). There is good 
evidence that mutations in the juxtamembrane segment and 
TKD found in cancers constitutively activate KIT by relieving 
the normal cis-autoinhibitory constraints in the TKD. In the KIT 
extracellular region, gain-of-function mutations in D5 map to 
the interface formed between two neighboring receptor mol-
ecules in a dimer induced by SCF binding (Figure 2B) (Yuzawa 
et al., 2007). These mutations are thought to stabilize intermo-
lecular interactions between two KIT D5 domains, promoting 
constitutive receptor-mediated dimerization by sufficiently 
strengthening receptor-receptor contacts to overcome the 
need for ligand.
Oncogenic Mutations and Alterations in the EGFR/ErbB 
Family
EGFR family receptors are overexpressed or mutated in sev-
eral human cancers. ErbB2, an orphan receptor that fails to 
form the tethered structure seen in the extracellular regions of 
other ErbB receptors (Burgess et al., 2003), is highly overex-
pressed as a result of gene amplification in ?30% of breast 
cancer patients. In addition, ErbB2 overexpression correlates 
with poor prognoses (Slamon et al., 1989). Although EGFR is 
overexpressed in several cancers, amplification of the EGFR-
encoding gene appears to be restricted to glioblastomas, where 
it occurs in ?35% of cases and leads to overexpression of both 
wild-type and mutated forms of the receptor (Libermann et al., 
1985). Several single-residue mutations in the EGFR extracel-
lular region (Figure S1) were reported in glioblastoma patients 
(Lee et al., 2006). A subset of these mutations may promote 
activation of the receptor by weakening the autoinhibitory 
tether. The most well known EGFR mutant in glioblastoma is 
variant III (vIII) or ∆2–7 EGFR (Figure S1), which lacks residues 
6–273 (encoded by exons 2–7) in the extracellular region of the 
wild-type receptor. This deletion encompasses all of domain 
I and most of domain II (Figures 1 and 2), including the key 
dimerization arm (Burgess et al., 2003). Biochemical stud-
ies of vIII EGFR indicate that it has constitutive (but low-level) 
tyrosine kinase activity. Reports of its ability to bind EGF and 
to dimerize vary (Pedersen et al., 2001), but the absence of 
the dimerization arm means that it cannot dimerize through the 
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same mechanism as the wild-type receptor. One possibility is 
that misfolding, due to the large extracellular deletion, causes 
vIII EGFR to aggregate in the endoplasmic reticulum resulting 
in constitutive activity of the receptor.
Recent studies in NSCLC provided important insights 
into regulation of the EGFR TKD (Sharma et al., 2007; Zhang 
et al., 2006). In clinical trials, only ?10% of NSCLC patients 
responded to EGFR-targeted TKD inhibitors, and these 
patients showed dramatic initial responses (Lynch et al., 2004). 
Sequencing of EGFR showed that all responding patients have 
somatic mutations in key regulatory elements of the EGFR TKD 
that disrupt normal cis-autoinhibitory interactions (Sharma et 
al., 2007; Zhang et al., 2006). Each of these EGFR mutations 
causes constitutive activation of the TKD by mimicking the 
conformational changes ordinarily promoted by the “Activator” 
kinase in the asymmetric dimer (Figure 2F). Intracellular jux-
tamembrane mutations have also been described in EGFR that 
activate the receptor, apparently by promoting ligand-indepen-
dent dimerization of the TKD (Red Brewer et al., 2009).
FGFR Mutations in Cancer and Other Pathologies
FGFR family members are also mutated in a variety of cancers. 
Chromosomal translocations, which result in the expression 
of dimeric (activated) fusion proteins containing the FGFR1 or 
FGFR3 TKDs, have been identified in lymphoblastic lymphoma, 
multiple myeloma, peripheral T cell lymphoma, and chronic 
myelogenous leukemia (CML). Germline activating FGFR3 
mutations (Figure S1) have been identified in 30% of bladder 
cancer and 25% of cervical carcinoma patients (Eswarakumar 
et al., 2005). Gain-of-function mutations in FGFR1, FGFR2, 
and FGFR3 also cause a variety of severe skeletal dysplasias 
(Eswarakumar et al., 2005).
Whereas activating germline mutations in FGFRs can cause 
craniosynostosis, skeletal dysplasia, and many cancers, muta-
tions that impair FGFR functions have a distinct set of impor-
tant pathological consequences. One example is seen in Kall-
mann Syndrome; this developmental disease is caused by 
inactivating FGFR1 mutations and is characterized by hearing 
loss, cleft palate, and tooth agenesis. Another developmen-
tal disease, LADD (lacrimo-ariculo-dento-digital) syndrome, is 
caused by mutations that impair the tyrosine kinase activity 
of the “b” isoform of FGFR2 or the activity of its ligand FGF10 
(Rohmann et al., 2006).
RTKs Are Important Drug Targets
Several drugs have been developed and approved by the US 
Food and Drug Administration (FDA) for treating cancers and 
other diseases caused by activated RTKs (Table S1). These 
drugs fall into two categories: small-molecule inhibitors that 
target the ATP-binding site of the intracellular TKD (Shawver 
et al., 2002) and monoclonal antibodies that both interfere with 
RTK activation and target RTK-expressing cells for destruction 
by the immune system (Reichert and Valge-Archer, 2007).
As might be expected for agents that target the ATP-bind-
ing site of protein kinases, many small-molecule RTK inhibi-
tors affect multiple tyrosine kinases in addition to their initially 
intended target. For example, imatinib (Gleevec) was initially 
identified in a program to develop PDGFR inhibitors, but it also 
potently inhibits KIT and the nonreceptor tyrosine kinase Abl. 
Imatinib has shown clinical activity in CML, which arises from 
constitutive tyrosine kinase activity of the aberrant Bcr-Abl 
fusion protein (Shawver et al., 2002). Imatinib has also been 
successfully applied to the treatment of GISTs, cancers that 
are primarily driven by constitutively activated KIT. Sunitinib 
(Sutent) also blocks the tyrosine kinase activities of several 
RTKs, including KIT, VEGFR2, PDGFR, Flt3, and Ret, and it has 
been successfully applied in the treatment of GIST and renal 
cell carcinoma (Chow and Eckhardt, 2007). On the other hand, 
the EGFR inhibitors erlotinib (Tarceva) and gefitinib (Iressa) 
show much greater specificity (Shawver et al., 2002) and are 
capable of selectively inhibiting EGFR under conditions where 
the closely related ErbB2 TKD is unaffected. Although sev-
eral tyrosine kinase inhibitors have been successfully applied 
to treat different cancers, key difficulties encountered during 
treatment include side effects that arise from a lack of selec-
tivity toward an individual target and the acquisition of drug 
resistance.
Monoclonal antibodies that bind to the extracellular domain 
of ErbB2 (trastuzumab/Herceptin) or EGFR (cetuximab/Erbitux 
and panitumumab/Vectibix) have been used to treat mammary 
carcinoma, colorectal cancer, and head and neck cancers, 
respectively (Reichert and Valge-Archer, 2007). A monoclo-
nal antibody directed against the VEGF ligand (bevacizumab/
Avastin) has also been used as an inhibitor of tumor angiogen-
esis for the treatment of colorectal, lung, and other cancers 
or diseases in which angiogenesis is important. Notably, the 
efficacy of the currently approved monoclonal antibodies for 
cancer therapy as single agents is very limited unless applied 
in combination with conventional chemotherapeutic agents. 
Moreover, because of their bivalent characteristics, several 
therapeutic antibodies that bind to receptors have been shown 
to function as weak RTK agonists that do not inhibit the activity 
of oncogenic RTKs with activating mutations in their TKDs.
It is now clear that drug resistance almost invariably develops 
in cancer patients treated with tyrosine kinase inhibitors or with 
monoclonal antireceptor antibodies. Selective pressure leads to 
the emergence of drug-resistant variants of the targets or to com-
pensations in the signaling networks that overcome the need for 
the inhibited RTK for continued growth (Engelman and Settle-
man, 2008; Sergina and Moasser, 2007). Mutations that abrogate 
the inhibitory activity of tyrosine kinase inhibitors are frequently 
seen in the TKD of the targeted RTK of tumor cells. For example, 
resistance of EGFR to inhibition by gefitinib is caused by T766M 
or T830A mutations (mature EGFR numbering) in the EGFR 
kinase domains of patients with lung adenocarcinomas (Bean et 
al., 2008; Sharma et al., 2007). Drug resistance to tumors treated 
with tyrosine kinase inhibitors or monoclonal antibodies against 
an RTK target has also emerged from compensatory activation 
or overexpression of a different RTK or other cell signaling pro-
teins. For example, upregulation of ErbB3 signaling via amplifi-
cation of the Met gene (Engelman et al., 2007) or through other 
mechanisms (Sergina and Moasser, 2007) overcomes growth 
inhibition by EGFR inhibitors. Upregulation of Met expression 
in breast cancer cells also promotes resistance to the ErbB2-
targeted Trastuzumab antibody (Shattuck et al., 2008). These 
findings and numerous other studies suggest that combining 
treatments that inhibit ErbB receptors and Met is likely to be 
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a useful strategy in the clinic, to overcome either Met-induced 
resistance to ErbB-targeted therapy (Engelman and Settleman, 
2008) or, conversely, ErbB receptor-induced resistance to Met-
targeted therapy. However, upregulation of still other RTKs can 
promote escape from targeted therapy. For example, VEGFR-1 
upregulation was found in cell lines with acquired resistance to 
EGFR-targeted inhibitors (Bianco et al., 2008).
It is anticipated that resistance will eventually develop toward 
every inhibitor that is targeted against RTKs. A key challenge for 
the future is to ascertain the range of possible escape mecha-
nisms. One obvious approach to resolving the problem of resis-
tance in the clinic is to apply combinations or series of different 
agents targeted against RTKs. However, as knowledge of the 
network properties of RTKs becomes more sophisticated, ther-
apeutic approaches that target the core processes engaged by 
all RTKs, such as PI-3K signaling (Engelman, 2009), may prove 
to be more robust than RTK-targeted agents alone.
Conclusions and Perspectives
Advances in our understanding of RTK signaling over the past 
quarter century have been dramatic. Basic investigations into the 
genetics, cellular biology, biochemistry, and structural biology of 
these receptors have yielded quite a sophisticated view of how 
this family of proteins functions. These findings have led to the 
development of numerous important therapeutics and serve as 
excellent examples of laboratory-driven translational research. 
Equally important, clinical analyses of RTKs in disease have pro-
vided substantial mechanistic insight (i.e., reverse-translational 
research), which in turn has allowed further refinement of thera-
peutic strategies. The molecular mechanisms underlying acti-
vation of RTKs share common themes among the families but 
differ markedly in their details. Only approximately half of the 
RTK families (Figure 1) are well understood, and completing this 
picture is a major challenge for the future, one that will surely 
provide many new lessons about RTK activation and signaling. 
At the level of the receptor molecules themselves, the impor-
tance of direct receptor crosstalk or heterodimerization for sig-
naling specificity remains unclear, as does the exact role played 
by intracellular trafficking. A quantitative understanding of these 
issues is another key challenge for the future.
Finally, as we appreciate the spatial, temporal, and chemi-
cal complexity of the signaling networks controlled by RTKs, 
it becomes increasingly clear that a quantitative biochemical 
understanding of the behavior of the systems is crucial for pre-
dicting qualitative outcomes. Although genetic and biochemi-
cal approaches have defined many signaling components in 
RTK networks, the next major challenge is to put these compo-
nents into mechanistic and quantitative contexts. This informa-
tion can then be used to develop new effective treatments for 
cancers and other diseases driven by activated RTKs.
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